Pharmacodynamic assessment of vancomycin-rifampicin combination against methicillin resistant Staphylococcus aureus biofilm: A parametric response surface analysis

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 1, 2011, Pages 73-79

  Salem, Ahmed H ^a,b   Elkhatib, Walid F ^a,b   Noreddin, Ayman M ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b African Union Organization St Abbassia   (Egypt)

^c HAMPTON UNIVERSITY   (United States)

Author keywords

biofilm; MRSA; response surface; rifampin; vancomycin

Indexed keywords

RIFAMPICIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BIOFILM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS;

ANTI-BACTERIAL AGENTS; BIOFILMS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MODELS, THEORETICAL; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 78650332499     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01183.x     Document Type: Article

References (49)

1. Wisplinghoff H, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
2. Haddadin AS, et al. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J 2002; 78: 385-392.
3. Klevens RM, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763-1771.
4. Abramson MA, Sexton DJ,. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999; 20: 408-411.
5. Engemann JJ, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36: 592-598.
6. Cosgrove SE, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36: 53-59.
7. Inoue Y, et al. Clinical evaluation of catheter-related fungemia and bacteremia. Intern Med 1995; 34: 485-490.
8. Hiramatsu K, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
9. Ploy MC, et al. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351: 1212.
10. Sieradzki K, et al. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340: 517-523.
11. Ikonomidis A, et al. Association of biofilm formation and methicillin-resistance with accessory gene regulator (agr) loci in Greek Staphylococcus aureus clones. Microb Pathog 2009; 47: 341-344.
12. Donlan RM, Costerton JW,. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-193.
13. Donlan RM,. Biofilms and device-associated infections. Emerg Infect Dis 2001; 7: 277-281.
14. McCann M, et al. Staphylococcus epidermidis device-related infections: pathogenesis and clinical management. J Pharm Pharmacol 2008; 60: 1551-1571.
15. Rice LB,. Unmet medical needs in antibacterial therapy. Biochem Pharmacol 2006; 71: 991-995.
16. Perlroth J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168: 805-819.
17. Raad I, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51: 1656-1660.
18. Saginur R, et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006; 50: 55-61.
19. LaPlante KL, Woodmansee S,. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother 2009; 53: 3880-3886.
20. Rose WE, Poppens PT,. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother 2009; 63: 485-488.
21. Rose WE, et al. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008; 52: 3061-3067.
22. Riedel DJ, et al. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2463-2467.
23. Rose WE, et al. Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function. J Antimicrob Chemother 2007; 59: 1190-1193.
24. Levine DP, et al. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-680.
25. Miller LG, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007; 44: 483-492.
26. Iyer S, Jones DH,. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004; 50: 854-858.
27. Tam VH, et al. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob Agents Chemother 2004; 48: 4315-4321.
28. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 6th edn. Approved standard. M7-A6. Wayne: Clinical and Laboratory Standards Institute, 2003.
29. Cernohorska L, Votava M,. Determination of minimal regrowth concentration (MRC) in clinical isolates of various biofilm-forming bacteria. Folia Microbiol (Praha) 2004; 49: 75-78.
30. Cernohorska L, Votava M,. Antibiotic synergy against biofilm-forming Pseudomonas aeruginosa. Folia Microbiol (Praha) 2008; 53: 57-60.
31. Christensen GD, et al. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol 1985; 22: 996-1006.
32. van Heerden J, et al. Antimicrobial coating agents: can biofilm formation on a breast implant be prevented? J Plast Reconstr Aesthet Surg 2009; 62: 610-617.
33. Noreddin AM, Elkhatib WF,. Novel in vitro pharmacodynamic model simulating ofloxacin pharmacokinetics in the treatment of Pseudomonas aeruginosa biofilm-associated infections. J Infect Public Health 2009; 2: 120-128.
34. D'Argenio DZ, Schumitzky A, Wang X,. ADAPT 5 User's Guide. Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource, 2009.
35. Baltch AL, et al. Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 1559-1562.
36. Cottarel G, Wierzbowski J,. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol 2007; 25: 547-555.
37. Mackay ML, et al. Comparison of methods for assessing synergic antibiotic interactions. Int J Antimicrob Agents 2000; 15: 125-129.
38. Cappelletty DM, Rybak MJ,. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 677-683.
39. Bonapace CR, et al. Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods. Diagn Microbiol Infect Dis 2000; 38: 43-50.
40. Craig W,. Pharmacodynamics of antimicrobials: general concepts and applications. In:, Nightingale CH, et al., ed. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Informa Healthcare, 2007: 1.
41. Hilf M, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87: 540-546.
42. Norden CW, et al. Comparison of techniques for measurement of in vitro antibiotic synergism. J Infect Dis 1979; 140: 629-633.
43. Saballs M, et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2006; 58: 697-700.
44. Boucher AN, Tam VH,. Mathematical formulation of additivity for antimicrobial agents. Diagn Microbiol Infect Dis 2006; 55: 319-325.
45. Costerton JW, et al. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-1322.
46. Shelburne SA, et al. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother 2004; 48: 4016-4019.
47. Mercier RC, et al. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002; 22: 1517-1523.
48. Watanakunakorn C, Guerriero JC,. Interaction between vancomycin and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 1981; 19: 1089-1091.
49. Chi CY, et al. Health care-associated endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. J Clin Microbiol 2008; 46: 810-813.